3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
70
Breast Neoplasms
64
Neoplasms
35
Carcinoma, Non-Small-Cell Lung
29
Neoplasm Metastasis
20
Triple Negative Breast Neoplasms
18
Lung Neoplasms
13
Ovarian Neoplasms
12
Adenocarcinoma
12
Stomach Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
10
Melanoma
10
Head and Neck Neoplasms
8
Fallopian Tube Neoplasms
7
Cholangiocarcinoma
7
Urinary Bladder Neoplasms
6
Recurrence
6
Esophageal Neoplasms
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Digestive System Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Uterine Cervical Neoplasms
4
Sarcoma, Ewing
4
Sarcoma
4
Prostatic Neoplasms
4
Pancreatic Diseases
4
Inflammatory Breast Neoplasms
4
Gallbladder Neoplasms
4
Endocrine Gland Neoplasms
4
Interventions
patritumab
1
Istiratumab
1
Gemcitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Fibromatosis, Gingival, 2
×
Albumin-Bound Paclitaxel
×
Clear all
NCT02399137
2018-09-18
CARRIE
Merrimack Pharmaceuticals
Phase 2
Completed
88 enrolled